HIF1A and anemia (phenotype): Similar concerns also exist for the clinical application of HIF inhibitors in the treatment of renal anemia [45], because the US FDA has recently approved Daprodustat, the first HIF prolyl hydroxylase (HIF-PH) inhibitor capable of blocking HIF-1 degradation, to treat anemia caused by chronic kidney disease (https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis, accessed on 1 February 2023).